Neimeth International Pharmaceuticals plc has signed a distribution agreement with WWCVL, a distribution company based in Lagos Nigeria.
Beyond distributing Neimeth products at the desired points of sale, WWCVL would also help to distribute support materials.
Speaking at the signing ceremony in Lagos, Emmanuel Ekunno, MD/CEO, Neimeth International Pharmaceuticals plc, who appreciated the partnership, said “the Pfizer genetics of Neimeth propelled by her DNA (Distinctive Novel Attributes) cuts across all her processes and every other thing, and as it has potentials for the level of partnership being entered into.”
According to Ekunno, “the partnership would be run as a team where mutual assistance would be given. To ensure the success of the partnership, Neimeth would engage in forward planning as a Plan of Action (POA) meeting is being scheduled for the month of April to foster harmony and create the much needed synergy between both Neimeth and WWCVL teams.”
Earlier in her opening remarks at the occasion, Roseline Oputa, director, sales and marketing Neimeth International Pharmaceuticals plc, said that the partnership evolved in December, 2014 and witnessed a progression that culminated in the signing of the Memorandum of Understanding (MoU).
While also responding, R.A.Narayan, MD/CEO of WWCVL, said his company, which specialises in only distribution, has a network of over 450 staff. Neimeth, he further said, is the first indigenous company WWCVL is partnering with.
Chris Mmeje, finance director, Neimeth International Pharmaceuticals plc, said the partnership had been factored in such a way that it will enhance WWCVL profitability and improve their business overall.
He also commended them for their expertise and professionalism which confer immense confidence on the partnership. At the ceremony were key members of Neimeth and WWCVL teams.
Iheanyi Nwachukwu
